IL15 and acute myeloid leukemia: However, data were conflicting, since remission rates of 35% were observed in relapsed/refractory AML upon haploidentical NK-cell infusions plus IL-15 [186], whereas a more recent study reported that systemic IL-15 resulted in reduced clinical responses to allogeneic adoptive cellular treatment [187].